Related Experiment Video

Updated: Jul 16, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Alovudine Targets mtDNA-dependent Proteins Encoded by Genes Recurrently Amplified in Metastatic Breast Cancer Cohorts

Jessica Brandi1, Gloria Gatto1, Federica Sotgia2

  • 1Department of Biotechnology, University of Verona, Verona, Italy.

Molecular & Cellular Proteomics : MCP
|July 14, 2026
PubMed

Insights

Alovudine treatment depletes mitochondrial DNA (mtDNA) in breast cancer cells, suppressing aggressive behaviors and metastasis. This drug action reveals potential therapeutic targets for advanced breast cancer by down-regulating key mitochondrial proteins.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • High mitochondrial DNA (mtDNA) levels correlate with "stemness" and aggressive phenotypes in human breast cancer cells, including metastasis.
  • Previous studies demonstrated Alovudine's ability to induce mtDNA-depletion in MDA-MB-231 cells, inhibiting colony formation and metastasis.

Purpose of the Study:

  • To elucidate the mechanisms underlying mtDNA's role in metastasis.
  • To identify mitochondrial protein biomarkers associated with metastatic breast cancer.
  • To investigate the therapeutic potential of Alovudine in targeting mtDNA-dependent pathways.

Main Methods:

  • Proteomics analysis of Alovudine-treated MDA-MB-231 cells.
  • Proteomics analysis of mtDNA-depleted MDA-MB-231 and MCF-7 cells.
  • Comparative analysis to identify commonly down-regulated proteins and associated nuclear-encoded mitochondrial genes.

Main Results:

  • Alovudine treatment and general mtDNA depletion commonly down-regulated a subset of mitochondrial proteins.
  • Over 20 nuclear-encoded mitochondrial genes, linked to these proteins, showed recurrent genomic amplification in metastatic breast cancer cohorts.
  • Alovudine effectively suppressed the expression of mitochondrial proteins associated with gene amplification and cancer cell metastasis.

Conclusions:

  • Alovudine demonstrates efficacy in suppressing key mitochondrial proteins involved in breast cancer metastasis and gene amplification.
  • Targeting mtDNA-dependent pathways with drugs like Alovudine holds promise for developing novel therapeutics for advanced breast cancer.
  • Identification of these mitochondrial proteins provides potential biomarkers for metastatic disease and therapeutic targets.
Keywords:
breast cancerlaovudinemetastasismitochondriamtDNAmtDNA-depleted cellsproteomics

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...